ArticleFrontiers in microbiology2022
Comparison of Anticancer Activities and Biosafety Between
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Review
- Engineering Salmonella as an immune-metabolic modulator of the tumor microenvironment.Trends in biotechnology · 2026Review
- Research progress and clinical translation challenges in the use of oncolytic bacteria for cancer therapy.Medical oncology (Northwood, London, England) · 2026Review
- Amodiaquine Enhances Anti-Melanoma Efficacy of Attenuated Salmonella via Targeting Glutathione Reductase in Neutrophils.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A clinically translatable, irreversibly attenuatedTheranostics · 2026Article
- Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies.Discover oncology · 2025Review
- Evaluation of tumor-colonizingmBio · 2025Article
- Living Bacteria: A New Vehicle for Vaccine Delivery in Cancer Immunotherapy.International journal of molecular sciences · 2025Review
- Synthetic biology approaches to enhance cancer immune responses.Frontiers in immunology · 2025Review
- Unlocking the potential of engineered microbes in immunotoxin-based cancer therapy.Frontiers in microbiology · 2025Review
- Advancing vaccine technology through the manipulation of pathogenic and commensal bacteria.Materials today. Bio · 2024Review
- Impact on Human Health ofInternational journal of molecular sciences · 2024Review
- The application of bacteria-nanomaterial hybrids in antitumor therapy.Journal of nanobiotechnology · 2024Review
- VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.Applied microbiology and biotechnology · 2024Article
- Review
- Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy.Theranostics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.